Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Staats K, Sosa BR, Kuyl E-, Niu Y, Suhardi V, Turajane K, et al. Intermittent parathyroid hormone increases stability and improves osseointegration of initially unstable implants. Bone Joint Res. 2022;11(5):260-269.

Liu J, Westblade LF, Wang F, Chadburn A, Fideli R, Craney A, et al. Distinct Laboratory Test Result Profiles Between SARS-CoV-2 and Seasonable Influenza Infected Patients. Ann Clin Lab Sci. 2022;52(6):871-879.

Boyraz B, Ly A. Discerning subsets of breast cancer with very low and absent HER2 protein expression. Hum Pathol. 2022;127:50-55.

Dadario NB, Pruitt R, Silverstein JW, Zlochower A, Teckie S, Harshan M, et al. Sarcomatous Change of Cerebellopontine Angle Ependymoma Following Radiosurgery: A Case Report. Cureus. 2022;14(1):e20864.

Taylor AS, Liu N, Fang JM, Panarelli N, Zhao L, Cheng J, et al. Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability. J Clin Pathol. 2022;75(7):483-487.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, et al. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. Front Genet. 2022;13:1096071.

Liu Y-, Illar GM, Amri RA, Canady BC, Rea B, Yatsenko SA, et al. Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis. Mod Pathol. 2022;35(5):625-631.

Raman R, Villefranc JA, Ullmann TM, Thiesmeyer J, Anelli V, Yao J, et al. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer. J Exp Med. 2022;219(6).

Smithgall MC, Murphy EA, Schatz-Siemers N, Matrai C, Tu J, Baergen RN, et al. Placental pathology in women vaccinated and unvaccinated against SARS-CoV-2. Am J Obstet Gynecol. 2022;227(5):782-784.

Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, et al. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clin Genitourin Cancer. 2022;20(4):301-306.